14th BioVaria to take place virtually on 26-28 April 2021
Technology sneak peek from Ascenion: Seven breakthrough life-science inventions
FDA approves Heidelberg Pharma’s IND for its antibody conjugate against cancer
Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.
Helmholtz Zentrum München and partners kick off new ITN project
16 partners from academia and industry will closely collaborate to prepare a future generation of scientists with outstanding skills in both machine learning and chemistry, to create new AI methods for drug research.
MHH to collaborate with Novo Nordisk in the field of lung diseases
Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.
Save the Date: next BioVaria from 26 to 28 April 2021
This year’s BioVaria is digital and takes place exclusively online from the 26 to 28 April 2021.
Welcome to the Team!
In December 2020 the Ascenion team gained two new colleagues: Dr Sören Rindfleisch in Hanover and Hubert Ludwiczak in München.
Ascenion receives ‘GO-Bio initial’ funding
As part of its ‘GO-Bio initial’ programme, the BMBF has awarded Ascenion funding for its 'Life Science Digital Hub' concept to improve support for GO-Bio initial applicants.
We would like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive…
New preclinical data further corroborate the potential of HepaRegeniX’s candidate against liver disease
Ascenion’s portfolio company HepaRegeniX achieves an important preclinical milestone indicating beneficial therapeutic effects of its lead candidate in certain liver carcinomas.
HZI project targeting hospital germs receives translational funding from CARB-X
An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.
Cardior’s lead compound against heart failure demonstrates excellent tolerability and safety
Ascenion’s portfolio company Cardior Pharmaceuticals announced positive results of a Phase Ib study with its first-in-class compound CDR132L.
Welcome to the team!
Ascenion welcomes a new colleague to the Munich office: Stefanie Danzer joined in October 2020 to support the back office in event management and corporate communications.
Ascenion is partner of ITN consortium ‘SMABEYOND’ on spinal muscular atrophy research
Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.
iThera to initiate a pivotal clinical trial with its optoacoustic imaging technology in inflammatory bowel disease (IBD)
Ascenion’s portfolio company iThera gained regulatory approval for a pivotal trial evaluating its MSOT imaging technology for the assessment of colon inflammation. If successful, it could provide a superior, non-invasive alternative to colonoscopy.
Biotech start-ups & zombies
How is the German start-up sector doing? Are there ‘zombies’ here too – as in the USA? And what should we be looking out for? A number of heads of German technology transfer organisations were interviewed for this overview, including Ascenion’s Christian Stein.